18 F-FDG PET/CT 联合血清 ANXA2、CXCL16 对非小细胞肺癌患者新辅助化疗疗效的评估价值OA
The evaluation value of 18 F-FDG PET/CT combined with serum ANXA2 and CXCL16 for the efficacy of neoadjuvant chemotherapy in patients with non-small cell lung cancer
目的 探究18 F-FDG PET/CT联合血清膜联蛋白A2(ANXA2)、C-X-C基序趋化因子配体16(CXCL16)对非小细胞肺癌(NSCLC)患者新辅助化疗(NAC)疗效的评估价值.方法 选取2023年4月—2025年6月徐州市第一人民医院/徐州医科大学附属徐州市立医院诊治的NSCLC患者180例(均行NAC治疗),根据NAC疗效分为有效组119例和无效组61例.ELISA检测血清ANXA2、CXCL16水平;采用多因素Logistic回归分析NSCLC患者NAC疗效的影响因素;相对危险度分析不同血清ANXA2、CXCL16水平对NSCLC患者NAC治疗无效的影响;受试者工作特征(ROC)曲线分析肿瘤代谢体积(MTV)、总糖酵解(TLG)及血清ANXA2、CXCL16水平对NSCLC患者NAC疗效的评估价值.结果 无效组MTV、TLG及血清ANXA2、CXCL16水平高于有效组(t/P=7.685/＜0.001、6.494/＜0.001、7.789/＜0.001、7.906/＜0.001);多因素 Logistic 回归分析显示,癌细胞低分化、MTV 高、TLG 高、ANXA2 高、CXCL16 高为 NSCLC 患者 NAC 治疗无效的危险因素[OR(95％CI)=3.056(1.334～7.002)、2.703(1.383～5.284)、2.238(1.270～3.943)、2.815(1.342～5.905)、2.976(1.380～6.417)];ANXA2、CXCL16 高水平的 NSCLC 患者 NAC 治疗无效风险为低水平的 1.576 倍、1.620 倍[95％CI=(1.209～2.053)和(1.256～2.088)];MTV、TLG、ANXA2、CXCL16 单独及四者联合评估NSCLC患者NAC疗效的曲线下面积(AUC)分别为0.738、0.727、0.760、0.770、0.912,四者联合优于各自单独评估(Z=2.512/＜0.001、2.537/＜0.001、2.493/＜0.001、2.486/＜0.001).结论 NAC 治疗无效的 NSCLC 患者 MTV、TLG及血清ANXA2、CXCL16水平升高,四者联合检测对NSCLC患者NAC疗效具有较高的评估价值.
Objective To explore the evaluation value of 18 F-FDG PET/CT combined with serum annexin A2(ANXA2)and C-X-C motif chemokine ligand 16(CXCL16)for the efficacy of neoadjuvant chemotherapy(NAC)in patients with non-small cell lung cancer(NSCLC).Methods From April 2023 to June 2025,180 NSCLC patients treated in the De-partment of Nuclear Medicine at Xuzhou First People's Hospital(Xuzhou Medical University Affiliated Xuzhou Municipal Hospital)were studied(all received NAC treatment).Based on NAC efficacy,they were divided into an effective group(119 cases)and an ineffective group(61 cases).Logistic regression was used to analyze the influencing factors of NAC efficacy in NSCLC patients,and relative risk was used to analyze the risk of treatment failure at different levels of ANXA2 and CXCL16.ROC curve analysis was used to evaluate the value of predicting NAC efficacy in NSCLC patients.Results The expression levels of MTV,TLG,serum ANXA2,and CXCL16 in the ineffective group were all significantly higher than those in the ef-fective group(t/P=7.685/＜0.001,6.494/＜0.001,7.789/＜0.001,7.906/＜0.001).Poorly differentiated tumor cells,high MTV,high TLG,high serum ANXA2,and high CXCL16 were independent risk factors for poor NAC response[OR(95％CI)=3.056(1.334-7.002),2.703(1.383-5.284),2.238(1.270-3.943),2.815(1.342-5.905),2.976(1.380-6.417)].The risk of NAC treatment failure in patients with high expression of ANXA2 and CXCL16 was 1.576 times and 1.620 times that of those with low expression,respectively[95％CI=(1.209-2.053),(1.256-2.088)].The AUCs for evaluating NAC efficacy in NSCLC patients using MTV,TLG,serum ANXA2,CXCL16,and their combination were 0.738,0.727,0.760,0.770,and 0.912,respectively.The combined assessment of the four indicators was superior to each individual assessment(Z=2.512,2.537,2.493,2.486;all P＜0.001).Conclusion MTV,TLG,and serum levels of ANXA2 and CXCL16 are elevated in NSCLC patients who do not respond to NAC treatment.Combined detection of these markers demonstrates high value in eval-uating the efficacy of NAC treatment in NSCLC patients.
陆园;王伟;张翔;任蒙蒙;宋英健;陈领振
221000 江苏省徐州市第一人民医院/徐州医科大学附属徐州市立医院核医学科221000 江苏省徐州市第一人民医院/徐州医科大学附属徐州市立医院核医学科221000 江苏省徐州市第一人民医院/徐州医科大学附属徐州市立医院核医学科221000 江苏省徐州市第一人民医院/徐州医科大学附属徐州市立医院核医学科221000 江苏省徐州市第一人民医院/徐州医科大学附属徐州市立医院核医学科221000 江苏省徐州市第一人民医院/徐州医科大学附属徐州市立医院核医学科
医药卫生
非小细胞肺癌新辅助化疗18 F-FDG PET/CT膜联蛋白A2C-X-C基序趋化因子配体16疗效评估
Non-small cell lung cancerNeoadjuvant chemotherapy18 F-FDG PET/CTAnnexin A2C-X-C motif chemokine ligand 16Therapeutic effect eveluation
《疑难病杂志》 2026 (5)
525-529,546,6
江苏省卫生健康委2022年度医学科研立项项目(KJS2022H0030) Medical Research Project Approved by the Health Commission of Jiangsu Province for the Year 2022(KJS2022H0030)
评论